Cargando…
No Difference in the Rate of Change in Telomere Length or Telomerase Activity in HIV-Infected Patients after Three Years of Darunavir/Ritonavir with and without Nucleoside Analogues in the MONET Trial
OBJECTIVE: To determine whether nucleos(t)ide reverse transcriptase inhibitors (NRTI) contribute to an accelerated loss in telomere length (TL) in HIV-infected patients on antiretroviral therapy (ART). DESIGN: Substudy of randomised controlled trial. METHODS: Patients with HIV RNA <50 copies/mL o...
Autores principales: | Solomon, Ajantha, Tennakoon, Surekha, Leeansyah, Edwin, Arribas, Jose, Hill, Andrew, Van Delft, Yvon, Moecklinghoff, Christiane, Lewin, Sharon R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219673/ https://www.ncbi.nlm.nih.gov/pubmed/25368992 http://dx.doi.org/10.1371/journal.pone.0109718 |
Ejemplares similares
-
The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL
por: Antinori, Andrea, et al.
Publicado: (2014) -
Analysis of major and minor IAS-USA PI mutations in the MONET trial of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs
por: Pulido, F, et al.
Publicado: (2010) -
Analysis of neurocognitive function and CNS endpoints in the PROTEA trial: darunavir/ritonavir with or without nucleoside analogues
por: Clarke, Amanda, et al.
Publicado: (2014) -
The MONET trial: correlation between Hepatitis C coinfection and HIV RNA responses during darunavir/ritonavir monotherapy, for patients with HIV RNA <50 copies/mL at baseline
por: Arribas, Jose R, et al.
Publicado: (2010) -
Low-level viraemia during treatment with darunavir/r monotherapy versus DRV/r + 2NRTIs in the MONET trial
por: Clumeck, N, et al.
Publicado: (2010)